Top Medical News
Guselkumab yields durable benefit in biologic-naïve PsA patients
5 days ago
The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
5 days ago
Chronic pain frequently occurs in patients with axial spondyloarthritis (axSpA), with no differences seen in any pain measures between those with ankylosing spondylitis (AS) and nonradiographic axSpA, a recent study has shown. In addition, higher pain sensitivity is predictive of having worse disease and health outcomes.
Colchicine cessation possible in familial Mediterranean fever with prolonged remission
6 days ago
Colchicine therapy may be discontinued after prolonged remission in some children with familial Mediterranean fever (FMF), suggests a study, noting, however, that patients with arthritis or myalgia are prone to an attack following treatment cessation.
Belimumab benefit sustained regardless of lupus nephritis status
Audrey Abella, 15 Nov 2021
The recombinant human IgG-1λ monoclonal antibody belimumab improved renal outcomes in patients with relapsed and newly diagnosed* active lupus nephritis (LN), according to subgroup analysis results of the BLISS-LN** trial presented at ASN 2021.
Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
13 Nov 2021
About a third of patients who present to an emergency department with recent-onset low back pain fail to recover within 12 months, with factors such as higher pain levels and more pain sites, among others, being prognostic of complete nonrecovery within 6 months, according to a study.
Rituximab biosimilars comparable to originator for advanced follicular lymphoma
07 Nov 2021
Rituximab maintenance dosing of 500 mg every 6 months may not be enough to maintain B cell depletion in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), suggests a recent study.
Denosumab inhibits joint destruction up to 3 years
06 Nov 2021
Treatment with denosumab prevents the progression of joint destruction up to 36 months, results of a Japan study have shown. Higher dosing frequency at an earlier treatment stage may help optimize treatment, based on effects on bone erosion score (BES) progression.
Special Reports
The ESCEO algorithm for the management of knee osteoarthritis (OA) and the role of symptomatic slow-acting drugs for OA (SYSA
03 Apr 2017
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
Conference Reports
Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes
Elaine Soliven, 24 Jun 2021
The use of apremilast consistently reduced the number and pain due to oral ulcers in both men and women with active Behçet’s syndrome, according to a subgroup analysis of the RELIEF* study presented at EULAR 2021.
TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization
Roshini Claire Anthony, 23 Jun 2021

Analysis of the German COVID-19 registry suggests that patients with rheumatic or musculoskeletal diseases (RMDs) who are treated with tumour necrosis factor (TNF) inhibitors appear to be at lower risk of severe outcomes of COVID-19 compared with those treated with other (non-TNF inhibitor) immunomodulatory treatments (OIDs).

Certain rheuma therapies tied to poorer COVID-19 outcomes, impaired vaccine response
Pearl Toh, 19 Jun 2021
Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.
Secukinumab promising for paediatric enthesitis-related arthritis and juvenile psoriatic arthritis
Roshini Claire Anthony, 18 Jun 2021

Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.

COSMOS: Guselkumab improves response rates in active psoriatic arthritis
Elaine Soliven, 18 Jun 2021
Treatment with guselkumab improved response rates in patients with active psoriatic arthritis (PsA) who had inadequate responses to tumour necrosis factor (TNF) inhibitors, according to the COSMOS* study presented at EULAR 2021.
COVID-19 vaccine safe in people with rheumatic diseases
Pearl Toh, 17 Jun 2021
Data from the EULAR COVID-19 Vaccination (COVAX) Registry showed that available COVID-19 vaccines were safe and well tolerated in patients with rheumatic and musculoskeletal diseases (RMDs).
KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis
Audrey Abella, 16 Jun 2021
The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.